Reuters logo
BRIEF- GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis
October 2, 2017 / 1:30 AM / in 21 days

BRIEF- GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis

Oct 2(Reuters) - GNI Group Ltd

* Says its wholly-owned subsidiary GNI USA, Inc had received U.S. FDA clearance on Sept. 29 (U.S. local time) for the Investigational New Drug application (IND) for F351 for U.S. clinical trials in the treatment of liver fibrosis

Source text in Japanese:goo.gl/wHgB1R

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below